A Model for Dosing Gentamicin in Children and Adolescents that Adjusts for Tissue Accumulation with Continuous Dosing

William E. Evans, R. Huntley Taylor, Sandor Feldman, William R. Crom, Gaston Rivera, Gary C. Yee

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The pharmacokinetics of gentamicin were evaluated in 50 children and adolescents during a multiple dose course of therapy. Parameters of a 2-compartment pharmacokinetic model were derived from serial serum concentrations and urinary excretion rates measured for up to 11 days following the last dose of gentamicin administered to 10 of these patients. These parameters were used to simulate changes in serum concentrations and half-lives that would occur during a standard 6-hour dosing interval with continuous dosing. The data indicated that the half-life for decline in serum concentrations after the first dose was 76 ± 8% of the half-life at steady-state, and that the half-life after the fourth dose exceeded 90% of the steady-state half-life. These underestimations of the steady-state serum half-life were incorporated into a 1 -compartment model to simulate steady-state peak and nadir serum concentrations by using pharmacokinetic parameters measured after the first dose of gentamicin administered to 40 patients. Steady-state serum concentrations predicted by the true 1 -compartment model and by the adjusted model were compared with concentrations measured at steady-state. The concentrations predicted by the former model were significantly different from and consistently less than measured concentrations. Concentrations predicted by the adjusted model were not significantly different from concentrations measured at steady-state. These data indicate that the new model offers a simple and more accurate method of simulating steady-state concentrations from pharmacokinetic parameters measured after initial doses of gentamicin and offers an improved model for individualising therapy. Supported by Biomedical Research Grant RR-005584 from the Division of Research Resourses, NIH; Childhood Solid Tumor Program Grant CA23099 from NCI; CORE Grant CA21765 from NCI, and by ALSAC.

Original languageEnglish (US)
Pages (from-to)295-306
Number of pages12
JournalClinical Pharmacokinetics
Volume5
Issue number3
DOIs
StatePublished - May 1980

Fingerprint

Gentamicins
Half-Life
Pharmacokinetics
Serum
Biomedical Research
Therapeutics
Research
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A Model for Dosing Gentamicin in Children and Adolescents that Adjusts for Tissue Accumulation with Continuous Dosing. / Evans, William E.; Huntley Taylor, R.; Feldman, Sandor; Crom, William R.; Rivera, Gaston; Yee, Gary C.

In: Clinical Pharmacokinetics, Vol. 5, No. 3, 05.1980, p. 295-306.

Research output: Contribution to journalArticle

Evans, William E. ; Huntley Taylor, R. ; Feldman, Sandor ; Crom, William R. ; Rivera, Gaston ; Yee, Gary C. / A Model for Dosing Gentamicin in Children and Adolescents that Adjusts for Tissue Accumulation with Continuous Dosing. In: Clinical Pharmacokinetics. 1980 ; Vol. 5, No. 3. pp. 295-306.
@article{8ba7bc6cc11c4f27873e62405c0a28cf,
title = "A Model for Dosing Gentamicin in Children and Adolescents that Adjusts for Tissue Accumulation with Continuous Dosing",
abstract = "The pharmacokinetics of gentamicin were evaluated in 50 children and adolescents during a multiple dose course of therapy. Parameters of a 2-compartment pharmacokinetic model were derived from serial serum concentrations and urinary excretion rates measured for up to 11 days following the last dose of gentamicin administered to 10 of these patients. These parameters were used to simulate changes in serum concentrations and half-lives that would occur during a standard 6-hour dosing interval with continuous dosing. The data indicated that the half-life for decline in serum concentrations after the first dose was 76 ± 8{\%} of the half-life at steady-state, and that the half-life after the fourth dose exceeded 90{\%} of the steady-state half-life. These underestimations of the steady-state serum half-life were incorporated into a 1 -compartment model to simulate steady-state peak and nadir serum concentrations by using pharmacokinetic parameters measured after the first dose of gentamicin administered to 40 patients. Steady-state serum concentrations predicted by the true 1 -compartment model and by the adjusted model were compared with concentrations measured at steady-state. The concentrations predicted by the former model were significantly different from and consistently less than measured concentrations. Concentrations predicted by the adjusted model were not significantly different from concentrations measured at steady-state. These data indicate that the new model offers a simple and more accurate method of simulating steady-state concentrations from pharmacokinetic parameters measured after initial doses of gentamicin and offers an improved model for individualising therapy. Supported by Biomedical Research Grant RR-005584 from the Division of Research Resourses, NIH; Childhood Solid Tumor Program Grant CA23099 from NCI; CORE Grant CA21765 from NCI, and by ALSAC.",
author = "Evans, {William E.} and {Huntley Taylor}, R. and Sandor Feldman and Crom, {William R.} and Gaston Rivera and Yee, {Gary C.}",
year = "1980",
month = "5",
doi = "10.2165/00003088-198005030-00007",
language = "English (US)",
volume = "5",
pages = "295--306",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - A Model for Dosing Gentamicin in Children and Adolescents that Adjusts for Tissue Accumulation with Continuous Dosing

AU - Evans, William E.

AU - Huntley Taylor, R.

AU - Feldman, Sandor

AU - Crom, William R.

AU - Rivera, Gaston

AU - Yee, Gary C.

PY - 1980/5

Y1 - 1980/5

N2 - The pharmacokinetics of gentamicin were evaluated in 50 children and adolescents during a multiple dose course of therapy. Parameters of a 2-compartment pharmacokinetic model were derived from serial serum concentrations and urinary excretion rates measured for up to 11 days following the last dose of gentamicin administered to 10 of these patients. These parameters were used to simulate changes in serum concentrations and half-lives that would occur during a standard 6-hour dosing interval with continuous dosing. The data indicated that the half-life for decline in serum concentrations after the first dose was 76 ± 8% of the half-life at steady-state, and that the half-life after the fourth dose exceeded 90% of the steady-state half-life. These underestimations of the steady-state serum half-life were incorporated into a 1 -compartment model to simulate steady-state peak and nadir serum concentrations by using pharmacokinetic parameters measured after the first dose of gentamicin administered to 40 patients. Steady-state serum concentrations predicted by the true 1 -compartment model and by the adjusted model were compared with concentrations measured at steady-state. The concentrations predicted by the former model were significantly different from and consistently less than measured concentrations. Concentrations predicted by the adjusted model were not significantly different from concentrations measured at steady-state. These data indicate that the new model offers a simple and more accurate method of simulating steady-state concentrations from pharmacokinetic parameters measured after initial doses of gentamicin and offers an improved model for individualising therapy. Supported by Biomedical Research Grant RR-005584 from the Division of Research Resourses, NIH; Childhood Solid Tumor Program Grant CA23099 from NCI; CORE Grant CA21765 from NCI, and by ALSAC.

AB - The pharmacokinetics of gentamicin were evaluated in 50 children and adolescents during a multiple dose course of therapy. Parameters of a 2-compartment pharmacokinetic model were derived from serial serum concentrations and urinary excretion rates measured for up to 11 days following the last dose of gentamicin administered to 10 of these patients. These parameters were used to simulate changes in serum concentrations and half-lives that would occur during a standard 6-hour dosing interval with continuous dosing. The data indicated that the half-life for decline in serum concentrations after the first dose was 76 ± 8% of the half-life at steady-state, and that the half-life after the fourth dose exceeded 90% of the steady-state half-life. These underestimations of the steady-state serum half-life were incorporated into a 1 -compartment model to simulate steady-state peak and nadir serum concentrations by using pharmacokinetic parameters measured after the first dose of gentamicin administered to 40 patients. Steady-state serum concentrations predicted by the true 1 -compartment model and by the adjusted model were compared with concentrations measured at steady-state. The concentrations predicted by the former model were significantly different from and consistently less than measured concentrations. Concentrations predicted by the adjusted model were not significantly different from concentrations measured at steady-state. These data indicate that the new model offers a simple and more accurate method of simulating steady-state concentrations from pharmacokinetic parameters measured after initial doses of gentamicin and offers an improved model for individualising therapy. Supported by Biomedical Research Grant RR-005584 from the Division of Research Resourses, NIH; Childhood Solid Tumor Program Grant CA23099 from NCI; CORE Grant CA21765 from NCI, and by ALSAC.

UR - http://www.scopus.com/inward/record.url?scp=0019141796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019141796&partnerID=8YFLogxK

U2 - 10.2165/00003088-198005030-00007

DO - 10.2165/00003088-198005030-00007

M3 - Article

C2 - 7389237

AN - SCOPUS:0019141796

VL - 5

SP - 295

EP - 306

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 3

ER -